Anaemia is a commonly diagnosed complication among patients suffering with chronic
kidney disease. If left untreated, it may affect patient quality of life. There are several causes …

Anemia and iron deficiency are common in patients with heart failure (HF), and are
associated with worse symptoms and adverse outcomes in this population. Although the two …

Background Non–placebo-controlled trials of erythropoiesis-stimulating agents (ESAs)
comparing lower and higher hemoglobin targets in patients with chronic kidney disease …

This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Description: The American College of Physicians (ACP) developed this …

Background Several erythropoiesis‐stimulating agents (ESAs) are available for treating
anaemia in people with chronic kidney disease (CKD). Their relative efficacy (preventing …

Erythropoietin (EPO) regulation of red blood cell production and its induction at reduced
oxygen tension provides for the important erythropoietic response to ischemic stress. The …

Abstract The European Renal Best Practice (ERBP), which are issued by ERA–EDTA, are
suggestions for clinical practice in areas in which evidence is lacking or weak, together with …

Background: Recombinant erythropoietin has become a routine component of care of
patients with chronic kidney disease reducing the need for blood transfusions but raising the …

Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Background: The benefits of anemia treatment in patients with heart disease are uncertain.
Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart …